



Bioventus Appoints Michelle McMurry-Heath to Board of Directors

December 21, 2021

DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- [Bioventus Inc.](#) (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company's Board of Directors, effective January 1, 2022.

Over the past 20 years, as both a physician and scientist, McMurry-Heath has served in dynamic policy, regulatory, commercial health care and advocacy roles. She will join the Board as an independent director.

"We are thrilled Michelle will be joining the Bioventus Board of Directors," said Ken Reali, CEO. "Bioventus will leverage her background as a global medical innovation strategist as well as her experience in global regulatory affairs, health care policy and valuable insights gained with the Food and Drug Administration as we grow our portfolio of offerings for pain treatments, restorative therapies and surgical solutions."

"It is my privilege to join the Bioventus Board. I am excited to bring my experience to the Company as it continues to grow globally and help them accelerate patient access to their products, as I believe medical innovation can improve lives and unlock opportunities for people around the world," said McMurry-Heath.

"We welcome Michelle to the Board and expect her opinion, perspective and critical thinking will serve as additional strategic guidance for Bioventus," said William Hawkins, Chairman of the Bioventus Board of Directors.

Currently, McMurry-Heath is President and Chief Executive Officer of the [Biotechnology Innovation Organization \(BIO\)](#), a membership and advocacy organization focused on strengthening opportunities for biotech research and applying biotech innovations to the biggest challenges of our age.

She previously served as Johnson & Johnson's Vice President, External Innovation, Global Leader for Regulatory Science and Executive Director of Scientific Partnerships for JLABS@DC. McMurry-Heath joined J&J in 2014, first as its Worldwide Vice President and Global Head, Regulatory Affairs and later adding responsibilities for the company's International Clinical Evidence and Strategic Operations.

Prior to that, she served as Associate Center Director for Science, Center for Devices and Radiological Health at the US Food and Drug Administration. From 2005 to 2010, McMurry-Heath was Director Health, Biomedical Science and Society Policy Program at the Aspen Institute.

McMurry-Heath began her career as a Senior Policy Advisor for Senator Joseph Lieberman for Health, Social, and Biomedical Innovation Policy. Later serving as a Robert Wood Johnson Health and Society Scholar at the University of California, San Francisco and Berkeley and a McArthur Fellow, Global Health for the Council on Foreign Relations.

She has an MD/PhD in Immunology from Duke University and received an AB in Biochemistry from Harvard University.

About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment, restorative therapies and surgical solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on [LinkedIn](#) and [Twitter](#). Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning Bioventus's future growth and strategy and the expected contributions of Ms. McMurry-Heath to the Company's Board. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release include, but are not limited to, the adverse impacts on our business as a result of the COVID-19 pandemic; our dependence on a limited number of products; our ability to develop, acquire and commercialize new products, line extensions or expanded indications; the continued and future acceptance of our existing portfolio of products and any new products, line extensions or expanded indications by physicians, patients, third-party payers and others in the medical community; our ability to differentiate the hyaluronic acid ("HA") viscosupplementation therapies we own or distribute from alternative therapies for the treatment of

Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO)



Michelle McMurry-Heath Joins Bioventus Board of Directors Effective January 1, 2022.

osteoarthritic; the proposed down-classification of non-invasive bone growth stimulators, including our Exogen system, by the U.S. Food and Drug Administration ("FDA"); our ability to achieve and maintain adequate levels of coverage and/or reimbursement for our products, the procedures using our products, or any future products we may seek to commercialize; our ability to recognize the benefits of our investments; our ability to complete acquisitions or successfully integrate new businesses, products or technologies in a cost-effective and non-disruptive manner; competition against other companies; the negative impact on our ability to market our HA products due to the reclassification of HA products from medical devices to drugs in the United States by the FDA; our ability to attract, retain and motivate our senior management and qualified personnel; our ability to continue to research, develop and manufacture our products if our facilities are damaged or become inoperable; failure to comply with the extensive government regulations related to our products and operations; enforcement actions if we engage in improper claims submission practices or in improper marketing or promotion of our products; the FDA regulatory process and our ability to obtain and maintain required regulatory clearances and approvals; failure to comply with the government regulations that apply to our human cells, tissues and cellular or tissue-based products; the clinical studies of any of our future products that do not produce results necessary to support regulatory clearance or approval in the United States or elsewhere; and the other risks identified in the Risk Factors section of the Company's public filings with the Securities and Exchange Commission ("SEC"), including Bioventus' Annual Report on Form 10-K for the period ended December 31, 2020, as updated by the Company's Quarterly Report on Form 10-Q for the quarter ended October 2, 2021, and as such factors may be further updated from time to time in Bioventus' other filings with the SEC, which are accessible on the SEC's website at www.sec.gov and the Investor Relations page of Bioventus' website at ir.bioventus.com. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company's business.

Media Contact:

Thomas Hill
919-474-6715
thomas.hill@bioventus.com

Investor Inquiries:

Dave Crawford
919-474-6787
dave.crawford@bioventus.com

A photo accompanying this announcement is available at <https://www.globenewswire.com/NewsRoom/AttachmentNg/af458422-7698-4592-9c18-3458db65248e>